.png){kind=icon}
.png){kind=icon}
Return
Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees
.png){kind=icon}
PRE
AI
S
F
G
F
A
DOI：10.1007/s10096-025-05304-4.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Recent advancements in tuberculosis (TB) treatment are reshaping how the disease is understood and managed, particularly through improved differentiation between TB infection and active disease, which enables more tailored treatment approaches. Rifapentine-based regimens are at the forefront, offering shorter treatment durations and better patient adherence, making them especially valuable for individuals living with HIV or managing multiple comorbidities. While these advancements offer great potential, the letter stresses the ongoing challenges faced by marginalized populations, including delayed diagnosis and poor access to quality care, which hinder global TB control efforts. It calls for availability of rifapentine in Europe to ensure equitable treatment access and support the WHO’s TB eradication goals.
Keywords:
Tuberculosis
Rifapentine
Migrants
Refugees
Europe
Journal
E
IF:
3
Papers:
7.1K
Citations:
1.1W
Organization
Cited Papers